Trial Profile

A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BOXR 1030 (Primary) ; Cyclophosphamide; Fludarabine
Indications Liposarcoma; Liver cancer; Lung cancer; Merkel cell carcinoma; Myxoid liposarcoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Acronyms DUET-01; DUET-1
Sponsors SOTIO

Most Recent Events

19 Dec 2024 Planned End Date changed from 1 Dec 2041 to 1 Dec 2042.
19 Dec 2024 Planned primary completion date changed from 1 Apr 2026 to 1 Oct 2027.
04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com